RT Journal Article
SR Electronic
T1 Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the Hologic Panther Fusion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.31.20185074
DO 10.1101/2020.08.31.20185074
A1 Cordes, Anne K.
A1 Rehrauer, William M.
A1 Accola, Molly A.
A1 Wölk, Benno
A1 Hilfrich, Birgitta
A1 Heim, Albert
YR 2020
UL http://medrxiv.org/content/early/2020/11/17/2020.08.31.20185074.abstract
AB The Hologic Panther Fusion (PF) platform provides fully automated CE marked diagnostics for respiratory viruses, including recently SARS-coronavirus 2 (SARS-CoV-2) by a transcription mediated amplification (TMA) assay, but not for the endemic human coronaviruses (hCoV). Therefore, a laboratory developed test (LDT) comprising a multiplexed RT-PCR protocol that detects and differentiates the four hCoV NL63, 229E, HKU1 and OC43 was adapted on the PF.The novel CE marked Aptima SARS-CoV-2 TMA and the LDT for hCoV were validated with 321 diagnostic specimens from the upper and lower respiratory tract in comparison to two SARS-CoV-2 RT-PCRs (PF E-gene RT-PCR and genesig RT-PCR, 157 specimens) or the R-GENE hCoV / hParaFlu RT-PCR (164 specimens), respectively.For the endemic hCoV, results were 96.3 % concordant with two specimens discordantly positive in the PF and four specimens discordantly positive in the R-GENE assay. All discordantly positive samples had Ct values between 33 and 39. The PF hCoV LDT identified 23 hCoV positive specimens as NL63, 15 as 229E, 15 as HKU1 and 25 as OC43. The Aptima SARS-CoV-2 TMA gave 99.4 % concordant results compared to the consensus results with a single specimen discordantly positive. Moreover, 36 samples from proficiency testing panels were detected and typed correctly by both novel methods.In conclusion, the SARS-CoV-2 TMA and the LDT for hCoV enhanced the diagnostic spectrum of the PF for all coronaviruses circulating globally for a multitude of diagnostic materials from the upper and lower respiratory tract.Competing Interest StatementAH: Research grant and travel grant not related to the present work by Hologic Inc. AC: Travel grant and speaker honorarium not related to the present work by Hologic Inc.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All 321 diagnostic samples originated from patients who had agreed to the anonymised use of their clinical data at hospital admission (informed consent). As specimens were tested according to diagnostic requests only and medical data were anonymized and analyzed only retrospectively, ethical approval is not required in Germany (confirmed by e-mails of the local ethical committee Ethikkommission der Medizinischen Hochschule Hannover, 19th of September, 2019 and 6th of May 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplmenentary data is included in the manuscript file